RNA Polymerase III Antibodies, IgG, Serum
Use
RNA Polymerase III antibodies are useful for evaluating patients suspected of having systemic sclerosis, providing diagnostic and prognostic information about the disease. Systemic sclerosis (SSc) is characterized by vascular dysfunction, fibrotic changes in the skin and internal organs, and an autoimmune response. Antibodies against RNA polymerases are typically present in patients with SSc and are associated with diffuse cutaneous forms of the disease, leading to poor prognosis and increased risk for hypertensive kidney disease.
Special Instructions
Not provided.
Limitations
The test relies on an immunodominant epitope from RNA polymerase III, which does not cover all epitopes in the RNA polymerase I/III antigens. A negative result does not rule out the presence of antibodies targeting other epitopes. False positives can occur due to immune complexes or immunoglobulin aggregates. The presence of antibodies does not necessarily correlate with the severity of systemic sclerosis, although high titers may indicate a greater likelihood of disease.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
RNA Polymerase III
Protein
LOINC Codes
- 79182-2 - RNAp III IgG SerPl IA-aCnc
- 79182-2 - RNAp III IgG SerPl IA-aCnc
Result Turnaround Time
2-7 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.3 mL
Minimum Volume
Not provided
Container
Serum gel preferred, red top acceptable; submission in a plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, gross lipemia, heat-treated specimen
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 21 days |
| Frozen | 21 days |